Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768110 | 0.84 | OPRD1 (0.44) | CHRM2OPRM1OPRD1OPRK1ACHE | |
| SCHEMBL28524727 | 0.81 | CHRM2 (0.53) | CHRM2OPRM1OPRD1OPRK1ACHE | |
| SCHEMBL28521333 | 0.81 | CHRM2 (0.51) | CHRM2OPRM1OPRD1OPRK1ACHE | |
| SCHEMBL768818 | 0.80 | CHRM2 (0.42) | CHRM2OPRM1OPRD1OPRK1ACHE | |
| SCHEMBL266338 | 0.79 | CHRM2 (0.65) | CHRM2CHRM3 | |
| SCHEMBL769137 | 0.79 | OPRD1 (0.43) | OPRM1OPRD1OPRK1ADRA1AADRA1B | |
| SCHEMBL28136567 | 0.78 | CHRM2 (0.39) | CHRM2OPRM1OPRD1OPRK1ACHE | |
| SCHEMBL28524774 | 0.78 | CHRM2 (0.68) | CHRM2OPRM1OPRD1ACHECHRM3 | |
| SCHEMBL768618 | 0.77 | OPRM1 (0.41) | OPRM1OPRD1OPRK1ADRA1AADRA1B | |
| SCHEMBL768952 | 0.76 | OPRM1 (0.44) | OPRM1OPRD1OPRK1ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | CHRM2 2/4885OPRM1 15/4885OPRD1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.